Ascendis Pharma Posts Strong 2025 Results as YORVIPATH Drives Growth and TransCon Pipeline Advances
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ascendis Pharma ( (ASND) ) has issued an update.
Ascendis Pharma reported on February 11, 2026 that fourth-quarter 2025 product revenue reached €240 million and full-year 2025 product revenue €684 million, driven mainly by YORVIPATH, while SKYTROFA contributed €206 million for the year. The company posted a Q4 2025 operating profit of €10 million, generated €73 million in operating cash flow, ended 2025 with €616 million in cash, and plans to start a €120 million share repurchase program in 2026.
Operationally, Ascendis highlighted rapid global uptake of YORVIPATH with more than 5,300 U.S. patient enrollments and availability in over 30 countries, plus commercial launches expected in 10 more markets by year-end 2026. The pipeline advanced with TransCon CNP under FDA priority review with a February 28, 2026 action date, an EMA filing, positive Phase 2 COACH data for TransCon CNP plus TransCon hGH, new Phase 3 and basket trials, and progress in oncology and partnered programs such as a Novo Nordisk obesity collaboration and VISEN’s Chinese approval of TransCon hGH.
These developments position Ascendis for a potential “steep growth phase” as management targets approximately €500 million in operating cash flow in 2026 and aspires to at least €5 billion in annual product revenue by 2030. Growing recurring product sales, broader geographic reach through partners like Teijin and VISEN, and a diversified late-stage pipeline strengthen its standing in the global biopharma market and may enhance value for shareholders and patients in endocrine, metabolic, and oncology indications.
The most recent analyst rating on (ASND) stock is a Buy with a $250.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
Spark’s Take on ASND Stock
According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.
Ascendis Pharma’s overall stock score is primarily influenced by its financial performance challenges, including high leverage and negative cash flows. While the earnings call provided positive insights into revenue growth and regulatory progress, the stock’s valuation remains unattractive due to ongoing losses. Technical indicators suggest a lack of strong momentum, further impacting the score.
To see Spark’s full report on ASND stock, click here.
More about Ascendis Pharma
Ascendis Pharma A/S is a Copenhagen-based biopharmaceutical company focused on endocrine and rare diseases, leveraging its TransCon technology platform to develop long-acting therapies. Its key marketed products include YORVIPATH (TransCon PTH) for hypoparathyroidism and SKYTROFA (TransCon hGH) for growth hormone deficiency, with an expanding global footprint through partners and label extensions.
Average Trading Volume: 706,463
Technical Sentiment Signal: Buy
Current Market Cap: $13.57B
See more insights into ASND stock on TipRanks’ Stock Analysis page.
